We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+25.49%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$918M
AUM Growth
+$52.7M
Cap. Flow
-$46.8M
Cap. Flow %
-5.1%
Top 10 Hldgs %
48.26%
Holding
70
New
15
Increased
16
Reduced
21
Closed
16

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$38.1M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$29.8M
3
AZN icon
AstraZeneca
AZN
+$18.5M
4
BLCM
Bellicum Pharmaceuticals, Inc.
BLCM
+$18.5M
5
BIIB icon
Biogen
BIIB
+$13.9M

Top Sells

Rank Stock Value
1
AGN
Allergan plc
AGN
+$39.5M
2
HCA icon
HCA Healthcare
HCA
+$23.2M
3
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
+$20.9M
4
CBST
CUBIST PHARMACEUTICALS INC
CBST
+$18.8M
5
WCG
Wellcare Health Plans, Inc.
WCG
+$15.3M

Sector Composition

Rank Sector Weight
1 Healthcare 85.78%
2 Miscellaneous 9.3%
3 Technology 2.51%
4 Communication Services 1.69%
5 Financials 0.72%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IHF icon
51
iShares US Healthcare Providers ETF
IHF
$1.23B
$296K 0.03%
12,500
-1,000
-7% -$22.5K
ALXN
52
DELISTED
Alexion Pharmaceuticals
ALXN
$257K 0.03%
+1,390
New +$258K
VIRX
53
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$64K 0.01%
+119
New +$53.6K
AGIO icon
54
Agios Pharmaceuticals
AGIO
$1.99B
– –
-49,200
Closed -$3.02M
ALGN icon
55
Align Technology
ALGN
$11.2B
– –
-172,772
Closed -$8.93M
BMRN icon
56
BioMarin Pharmaceuticals
BMRN
$12.5B
– –
-177,079
Closed -$12.8M
HCA icon
57
HCA Healthcare
HCA
$90.5B
– –
-328,292
Closed -$23.2M
OEF icon
58
PUT
iShares S&P 100 ETF
OEF
$20.5B
– –
-450,000
Closed -$49.2M
PRTA icon
59
Prothena Corp
PRTA
$479M
– –
-125,973
Closed -$2.79M
ICPT
60
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
– –
-2,212
Closed -$524K
CSII
61
DELISTED
Cardiovascular Systems, Inc.
CSII
– –
-370,208
Closed -$8.75M
OTIC
62
DELISTED
Otonomy, Inc.
OTIC
– –
-18,400
Closed -$442K
CLVS
63
CALL
DELISTED
Clovis Oncology, Inc.
CLVS
– –
-100,000
Closed -$4.54M
HMSY
64
DELISTED
HMS Holdings Corp.
HMSY
– –
-303,571
Closed -$5.72M
MNK
65
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
– –
-231,389
Closed -$20.9M
AGN
66
DELISTED
Allergan plc
AGN
– –
-163,898
Closed -$39.5M
CYBX
67
DELISTED
CYBERONICS INC
CYBX
– –
-172,900
Closed -$8.85M
KYTH
68
DELISTED
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
– –
-281,479
Closed -$9.22M
CBST
69
DELISTED
CUBIST PHARMACEUTICALS INC
CBST
– –
-283,756
Closed -$18.8M
1 2
3

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q4 2014 Portfolio in Review

As of Q4 2014, Redmile Group held 70 positions worth $918M, up 6.1% from $866M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Redmile Group withdrew a net $46.8M in Q4 2014, closing 16 positions and reducing 21 holdings. Its most notable exit was Allergan plc, an estimated $39.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 76% a quarter earlier, followed by Miscellaneous and Technology.

Against the trend, Redmile Group opened a new position in Gilead Sciences worth $34.7M.

  • Redmile Group's largest Q4 2014 buy was Gilead Sciences: 368,615 shares worth $34.7M.
  • Redmile Group added most to Seagen Inc. Common Stock in Q4 2014, an estimated $29.8M increase.
  • Redmile Group's biggest Q4 2014 reduction was Wellcare Health Plans, Inc., cutting an estimated $15.3M.
  • Redmile Group fully exited Allergan plc in Q4 2014, selling an estimated $39.5M.
  • Redmile Group's ten largest holdings make up 48% of its $918M portfolio in Q4 2014.
  • Redmile Group opened 15 new positions and closed 16 in Q4 2014.
  • Redmile Group's portfolio value rose 6.1% quarter-over-quarter to $918M.

Based on Redmile Group's 13F filing for Q4 2014, filed 18 Feb 2015.